We recommend that you upgrade to the latest version of your browser.

Om PBCB og forskningsgruppene

Her kan du lese om PBCB og forskningsgruppene knyttet til prosjektet.

I Norge blir over 4000 kvinner og rundt 30 menn rammet av brystkreft hvert år, og over 60 000 kvinner lever i dag etter å ha gått gjennom behandling for bystkreft.

Til tross for at prognosene for denne pasientgruppen generelt er gode, vil en del pasienter oppleve at bivirkninger etter behandlingen i varierende grad reduserer livskvaliteten. I tillegg er det en risiko for at man kan rammes av tilbakefall av sykdommen. Det er derfor et behov for å følge opp disse pasientene jevnlig for å kartlegge livskvaliteten, og for å samle inn flytende biopsier, som for eksempel blod- eller urinprøver.

Kunnskapen fra denne oppfølgingen vil på sikt kunne bidra til å optimalisere brystkreftbehandlingen, minske bivirkninger og oppdage potensielle tilbakefall på et tidlig tidspunkt – slik at nødvendig behandling kan startes opp så raskt som mulig.

Siden 2012 har PBCB samlet inn blodprøver og urinprøver (flytende biopsier), i tillegg til kliniske opplysninger og pasientrapporterte data (spørreskjemaer/PROM) av 1455 pasienter som er operert for brystkreft på enten Haukeland (HUS) eller Stavanger universitetssjukehus (SUS). Denne innsamlingen muliggjør flere viktige typer studier på brystkreft i vår region, og danner grunnlag for forskningssamarbeid både nasjonalt og internasjonalt.

The PBCB research group at Haukeland University Hospital consists of researchers and clinicians from the hormone laboratory and the endocrine surgery department.

The hormone laboratory's research group is led by Professor Gunnar Mellgren. The group researches breast cancer with a focus on endocrine treatment and advanced drug analysis (mass spectrometry).

In addition, the group works on a number of projects focusing on obesity, nutrition, and type 2 diabetes. The group is affiliated with the Mohn Nutrition Research Laboratory and Clinical Institute 2 at the University of Bergen (UiB.no).

The endocrine surgery department is led by Dr Anette Heie, and the department has been central to the collection of patient samples and questionnaires for PBCB. Research projects have been conducted at this department that have mapped side effects and psychosocial challenges related to breast cancer treatment.

The PBCB research group at Stavanger University Hospital is an interdisciplinary research group consisting of research coordinators, researchers, and clinicians from the department of surgery, the department of pathology, the department of blood and cancer diseases, and the research department. The research group also includes user representatives. The group was founded by Professor and Surgeon Håvard Søiland, but is currently led by Chief Engineer and Researcher Kjersti Tjensvoll.  

Department of Pathology

At the Department of Pathology, several studies have been conducted based on previously archived tumour tissue from breast cancer patients collected between 1989 and 2004. These studies are a combination of classical pathology, molecular biology, quantitative immunohistochemistry, and digital pathology. The overarching aim of the studies is to improve current breast cancer diagnostics.

Section for Molecular Quantitative Pathology - Helse Stavanger HF 

Breast and Endocrine Surgical Section

The Department of Surgery, Breast and Endocrine Surgical Section is a clinical section that annually operates on around 350 patients with breast cancer. In recent years, the section has participated in several clinical studies focusing on surgical methods and side effects and complications related to treatment. The section is responsible for the inclusion and follow-up of patients participating in PBCB at SUS and currently has a PhD student researching endocrine treatment in oestrogen-sensitive breast cancer in these patients.  

Breast and Endocrine Surgical Outpatient Clinic - Helse Stavanger HF 

Department of Blood and Cancer Diseases

At the Department of Blood and Cancer Diseases, breast cancer research has long emphasised the development of methods to detect possible disease recurrence earlier than current technology allows. Detection of so-called micrometastases in bone marrow in patients with breast cancer (early stage) has long been the focus of research here.

In recent years, however, research has shifted more towards investigating the significance of circulating tumour cells (CTCs) and cell-free tumour DNA (ctDNA) from plasma as markers to predict disease recurrence, and as a tool to measure treatment effect. 

Cancer and Medical Physics - Helse Stavanger HF

Finansieringskilder

  • Folke Hermansen fond 
  • Helse Vest 
  • Inge Steenslands Stiftelse 
  • Nasjonalt nettverk for brystkreftforskning 
  • Interne forskningsfond ved HUS og SUS 
Last updated 4/29/2026